Overview
If your child is 4 to 5 years of age and has ADHD, they are invited to take part in a research study evaluating the effectiveness and safety of extended-release viloxazine for ADHD symptoms in preschool-age children compared to a placebo. Participation involves 8 clinic visits over about 8 weeks.
Eligibility
InclusionChild is 4 to 5 years of age; has ADHD
Location
Kennedy Krieger Institute, Johns Hopkins
Sponsor & Collaborators
SponsorKennedy Krieger Institute
Study Flyer
